| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.transgenebiotek.com | |
| Market Cap | 26.22 Cr. | |
| Enterprise Value(EV) | 36.33 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -1.37 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 39.15 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 1.56 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 2.06 | Calculated using Price: 3.21 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 7.58 Cr. | 75,770,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies. | ||
| 1 Day |
|
-3.31% |
| 1 Week |
|
-5.31% |
| 1 Month |
|
-9.32% |
| 3 Month |
|
-17.90% |
| 6 Month |
|
-27.87% |
| 1 Year |
|
-29.61% |
| 2 Year |
|
-52.02% |
| 5 Year |
|
+8.81% |
| 10 Year |
|
-83.62% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | -0.64 | -50.54 | -9.63 | -11.78 | -17.03 | -11.57 | -18.31 | -28.73 | -38.00 | |
| Return on Capital Employed (%) | -0.54 | -47.36 | -8.84 | -10.85 | -14.68 | -6.74 | -14.83 | -22.10 | -26.55 | |
| Return on Assets (%) | -0.55 | -36.70 | -5.45 | -6.56 | -7.77 | -3.35 | -4.84 | -6.39 | -6.45 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 322 | 206 | 191 | 174 | 59 | 52 | 44 | 33 | 22 | 17 | |
| Non Curr. Liab. | 12 | 127 | 127 | 127 | 127 | 120 | 120 | 120 | 120 | 121 | |
| Curr. Liab. | 35 | 26 | 25 | 11 | 12 | 14 | 13 | 14 | 14 | 9 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 369 | 358 | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | |
| Non Curr. Assets | 348 | 338 | 326 | 310 | 197 | 186 | 176 | 166 | 156 | 146 | |
| Curr. Assets | 21 | 20 | 18 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 369 | 358 | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 15 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other Income | 0 | 1 | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 0 | |
| Total Income | 15 | 2 | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 0 | |
| Total Expenditure | -16 | -3 | -2 | -1 | -3 | -2 | -1 | -1 | -1 | -1 | |
| PBIDT | -1 | -1 | -2 | -1 | -2 | 5 | 1 | -1 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | ||
| Depreciation | -1 | -17 | -17 | -21 | -18 | -10 | -10 | -10 | -10 | -10 | |
| Taxation | -1 | ||||||||||
| Exceptional Items | -115 | ||||||||||
| PAT | -2 | -133 | -19 | -22 | -20 | -6 | -9 | -11 | -10 | -10 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -2 | -133 | -19 | -22 | -20 | -6 | -9 | -11 | -10 | -10 | |
| Adjusted EPS | 0 | -18 | -3 | -3 | -3 | -1 | -1 | -1 | -1 | -1 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 25 | 13 | -2 | 4 | 6 | 0 | -1 | -2 | 0 | 0 | |
| Cash Fr. Inv. | -144 | -15 | 1 | -5 | -6 | 3 | 2 | 0 | |||
| Cash Fr. Finan. | 83 | 2 | 1 | 1 | -2 | 0 | |||||
| Net Change | -36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Wed, 08 Jun 2022
Revised Declaration Of Unmodified Opinion On Standalone And Consolidated Audited Annual Financial Results For Year Ended 31 March 2022. With reference to email from BSE Ltd dated 7th June 2022 we hereby submit revised Declaration of unmodified opinion on Standalone and Consolidated Audited Annual Financial Results for year ended 31 March 2022 along with complete financial results. |
|
Thu, 02 Jun 2022
REVISED COMPLIANCE CERTIFICATE AS PER CLAUSE 40(9). We are enclosing hereto the Revised Compliance Certificate As Per Clause 40(9) in the prescribed format for the year ended 31st March 2022 |
|
Mon, 30 May 2022
Board Meeting Outcome for Outcome Of Board Meeting This with reference to our letter dated May 08 2022. Acordingly the Board has Considered and Approved the Audited Consolidated & Stand-alone Financial Statement for the Quarter and Financial Year ended 31.03.2022 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules 2015 along with Auditors Report submitted by M/s. Manisha Dubey & Associates Chartered Accountants. This is for your kind information and records. |
| Mon, 27 Jun 2022 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Close Within 52 Week Low Zone
|
High Decrease 3 Months
|
Equities
M.F.
Sectors